How Johnson & Johnson Vision is Supporting the Community During the COVID-19 Pandemic
We're committed to helping individuals and communities around the world manage the unprecedented impacts of COVID-19.
The values that guide our decision-making are spelled out in Our Credo. Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.
Over 1,300 Packs of ACUVUE® Contact Lenses Donated to Medical Workers
To help physicians and nurses in Wuhan see under their required protective goggles, which can be challenging while also wearing glasses, the Johnson & Johnson Vision team in China moved quickly to provide packs of disposable prescription contact lenses.
Supporting Existing and Future Eye Care Professionals Through Virtual Education
Helping Optometry Students Graduate
With several colleges of optometry limiting clinic operations in the U.S. due to COVID-19, student graduations were at risk of being delayed for most of the optometry class of 2020 nationwide.
As part of our commitment to supporting the next generation of eye care professionals, our team of experts, in partnership with the American Academy Of Optometry and Association of Schools and Colleges of Optometry, created the Student Online Clinical Case Education Program, a series of virtual educational sessions to help students meet graduation requirements.
Vision Masters Webinar Series
To support professionals in these uncertain times, we are providing a variety of digital educational resources.
Vision Masters, a 10-part weekly webinar series explores technologies to maximize patient outcomes. Attendees will receive an in-depth look at the latest in cataract, refractive surgery and ocular surface advancements.
March 27: Johnson & Johnson announced a $50 million commitment to support frontline health workers battling COVID-19.
March 30: Johnson & Johnson announced a lead vaccine candidate will move into trials and pledges to supply one billion vaccines worldwide for emergency pandemic use. BARDA and Johnson & Johnson commit $1 billion to vaccine R&D.